Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

W004 - Hands-on: Lasers

Monday, February 19; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Discuss current indications and treatment protocols for laser and light treatments including vascular, tattoo, pigment, nonablative, fractional, and ablative lasers.
  • Identify appropriate patients and gain treatment pearls for skin tightening, fat melting, and body contouring procedures.
  • Utilize proper laser techniques, and treat a variety of dermatologic conditions with laser and light devices.

Description

This session is geared toward all levels of dermatologists, from beginner and intermediate to advanced levels. It offers small groups, hands-on experience practicing a variety of laser skills and techniques. Approaches to patient assessment and selection, treatment planning, equipment selection, laser safety, and proper application of devices will be covered. Small groups will rotate between stations demonstrating ablative resurfacing, nonablative rejuvenation, tattoo and pigment removal, acne and vascular lesions, skin tightening, fat melting, and body contouring. Participants will complete a pre- and post-assessment of procedural skills covered in this session. This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.

Disclosures

  • Avram, Mathew M., MD, JD: Allergan, Inc – C(Fees); Cytrellis Biosystems, Inc – C(ST); Invasix – C(Fees); Masters of Aesthetics, Inc. – F(Fees); Merz Aesthetics – C(Fees); Sciton Inc. – A(Fees); Sienna Biopharmaceuticals – A(Fees); Zalea, LLC – C(Fees); Zeltiq Aesthetics – C(Fees);
  • Bernstein, Eric F., MD: Candela Corporation – A(Fees); Syneron, Inc. – I(Grants/Research Funding); Zeltiq Aesthetics – A(H), I(Grants/Research Funding);
  • DiGiorgio, Catherine M, MS, MD: no financial relationships exist with commercial interests.
  • Kelly, Kristen Marie, MD: Allergan, Inc – C(H), I(Grants/Research Funding); Asclepion Laser Technologies GmbH – O(EQ); Candela Corporation – O(EQ), O(NC); Light Sciences Oncology – I(EQ); New Star Lasers – I(EQ); Reliant Technologies, Inc. – O(EQ); Thermage – O(EQ);
  • Kilmer, Suzanne L., MD: Allergan, Inc – I(Grants/Research Funding); Cutera, Inc. – I(Grants/Research Funding); Cynosure, Inc. – I(Grants/Research Funding); Cytrellis Biosystems, Inc – A(Grants/Research Funding); Galderma USA – A(H); Lumenis – I(Grants/Research Funding); Lutronics, Inc. – I(Grants/Research Funding); Merz Aesthetics – I(Grants/Research Funding); Miramar Labs – A(H); R2 Dermatology, Inc. – I(Grants/Research Funding); Sebacia, Inc. – I(Grants/Research Funding); Sienna Labs, Inc. – A(H); Solta Medical – I(Grants/Research Funding); Syneron Candela – A(Grants/Research Funding); Zarin Medical – A(H); Zeltiq Aesthetics – A(H); Zift Medical – A(H);
  • Lee, Kachiu Cecilia, MD, MPH: no financial relationships exist with commercial interests.
  • Levin, Yakir S, MD, PhD: no financial relationships exist with commercial interests.
  • Onwudiwe, Oge C., MD: no financial relationships exist with commercial interests.
  • Ortiz, Arisa, MD: Alastin Skincare, Inc – C(H); Allergan, Inc – A(H), SH(NC), SP(H); BTL Industries – O(EQ); Cutera, Inc. – I(EQ); InMode MD Ltd – A(H), SP(H); Merz Aesthetics – A(H); Rodan and Fields – A(H); Sciton Inc. – A(H), SP(H); Ulthera – Data Safety Monitoring Board(H);
  • Sadick, Neil S., MD: Allergan, Inc. – C(H), O(H); Almirall – C(H); Amgen – I(Grants/Research Funding); Carma Laboratories, Inc – O(H); Cassiopea SpA – I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding), SP(H); Cutera, Inc. – I(Grants/Research Funding), SP(H); Cynosure, Inc. – C(H), I(Grants/Research Funding); Derm Advance – SH(SO); DS Laboratories – I(Grants/Research Funding); Eclipse Medical – O(H); Eli Lilly and Company – I(Grants/Research Funding); Endo International plc – C(H), I(Grants/Research Funding); EndyMed Medical Inc. USA – SP(H); Eternogen – C(SO); Foamix – I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), O(H); Galderma USA – I(Grants/Research Funding); Gerson Lehrman Group – C(H); Hydropeptide, LLC – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – I(Grants/Research Funding); Merz Aesthetics – A(H), C(H); Neostrata – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Nutraceutical Wellness, LLC. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Prescriber's Choice – O(H); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Regeneron – I(Grants/Research Funding); Roche Laboratories – I(Grants/Research Funding); Slender Medical Ltd. – SH(SO); Solta Medical – O(H), SP(H); Storz Medical AG – SP(H); Valeant Pharmaceuticals International – C(H), I(Grants/Research Funding), O(H); Vanda Pharmaceuticals Inc. – I(Grants/Research Funding); Vascular Insights, LLC – SH(SO); Venus Concept – C(SO), I(Grants/Research Funding), SP(H);
  • Saedi, Nazanin A., MD: Aerolase – I(EQ); Alastin Skincare, Inc – C(Fees); Cartessa Aesthetics – C(EQ); Cynosure, Inc – O(EQ);
  • Saluja, Sandeep, MD: no financial relationships exist with commercial interests.
  • Stankiewicz, Kelly J., MD: Cutera, Inc. – C(H), SP(H);
  • Weiss, Robert A., MD: Allergan, Inc – A(H), C(Fees), C(H); Allergan, Inc. – I(Grants/Research Funding); Brickell Biotech, Inc. – I(Grants/Research Funding); BTL Industries – I(Grants/Research Funding); Cutanea Life Sciences – I(Grants/Research Funding); Cutera, Inc. – Speaker/Faculty Education(Fees); Cynosure, Inc – A(Fees), I(Grants/Research Funding); Cynosure, Inc. – SP(Fees); Evolus, Inc. – I(Grants/Research Funding); Fibrocell Sciences – I(Grants/Research Funding); Galderma Laboratories, L.P. – I(Grants/Research Funding); Galderma USA – SP(H); Lutronic – I(Grants/Research Funding); Lutronics, Inc. – SP(H); Merz Aesthetics – A(H), I(Grants/Research Funding), SP(Fees); Merz Pharmaceuticals, LLC – C(H); Revance Therapeutics, Inc. – I(Grants/Research Funding); Sapheon, Inc. – I(Grants/Research Funding); Sebacia, Inc. – I(Grants/Research Funding); SkinCeauticals LLC – A(Fees); Syneron Candela – A(IP), I(Grants/Research Funding), SP(Fees); ThermiAesthetics – SP(H); Valeant Pharmaceuticals International – I(Grants/Research Funding); Zeltiq Aesthetics – I(Grants/Research Funding);
  • Wulkan, Adam, MD: no financial relationships exist with commercial interests.
  • Xu, Lisa Y., MD: no financial relationships exist with commercial interests.
Event Details
  • Date
    Monday, February 19
  • Time
    9:00 AM - 12:00 PM
  • Location
    Room 10
  • CME Credits
    3.00
  • Type
    Ticketed
    MOC
    Restricted
Directors/Co-Directors
  • Mathew M. Avram, MD, JD, FAAD
  • Arisa Ortiz, MD, FAAD
Speakers
  • Adam Wulkan, MD
  • Catherine M DiGiorgio, MS, MD, FAAD
  • Eric F. Bernstein, MD, FAAD
  • Kachiu Cecilia Lee, MD, MPH, FAAD
  • Kelly J. Stankiewicz, MD, FAAD
  • Kristen Marie Kelly, MD, FAAD
  • Lisa Y. Xu, MD, FAAD
  • Nazanin A. Saedi, MD, FAAD
  • Neil S. Sadick, MD, FAAD
  • Oge C. Onwudiwe, MD, FAAD
  • Robert A. Weiss, MD, FAAD
  • Sandeep Saluja, MD
  • Suzanne L. Kilmer, MD, FAAD
  • Yakir S Levin, MD, PhD, FAAD